Compare DECK & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | VTRS |
|---|---|---|
| Founded | 1973 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9B | 14.8B |
| IPO Year | 1993 | N/A |
| Metric | DECK | VTRS |
|---|---|---|
| Price | $117.37 | $15.73 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 6 |
| Target Price | ★ $122.20 | $11.83 |
| AVG Volume (30 Days) | 3.2M | ★ 9.4M |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.04% |
| EPS Growth | ★ 14.09 | N/A |
| EPS | ★ 7.01 | N/A |
| Revenue | $5,374,707,000.00 | ★ $14,124,400,000.00 |
| Revenue This Year | $10.94 | N/A |
| Revenue Next Year | $7.34 | $1.29 |
| P/E Ratio | $16.50 | ★ N/A |
| Revenue Growth | ★ 9.16 | N/A |
| 52 Week Low | $78.91 | $6.85 |
| 52 Week High | $159.26 | $16.30 |
| Indicator | DECK | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 63.95 | 78.16 |
| Support Level | $113.40 | $14.10 |
| Resistance Level | $119.57 | $16.30 |
| Average True Range (ATR) | 4.19 | 0.45 |
| MACD | 0.51 | 0.16 |
| Stochastic Oscillator | 89.01 | 84.47 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.